No, I don't. I haven't been in this that long. My average is at 1.89, holding 40K. Too many catalyst for this co this year. Increasing number of eyes on this co. It will go steady towards double once we past tomorrows hurdle.
I like your idea. I have biomedical degree, but have been out of the field for 18 years. Wanna partner up?
Wasn't thrilled with that CC either. "we should be able to get the required studies under way - we think" is not a confidence.
Learn to read the charts! The pump & dump hasn't been started, yet. But it's coming soon. AEZS should be hearing from FDA anytime soon on their NDA submission. With this P&D, new high will be established, then steady climb through ADCOM or PDUFA.
So they are the only 2 qualified out of 11?
About 75% of the time, FDA follows panel decision. I can understand if the vote was close, but 9:2 is far from close!
One can dream. ADCOM panel voted down 9:2. Majority of times, FDA follows panel decisions. If it was more like 6:5 or even 7:4, FDA might consider, but 9:2???
Copy/paste, but good info. We should all do our DD, and be able to dissect the info. In other hand, biotech is news and catalyst driven. ETRM can sink or pop any time on pure pump&dump. Next catalyst on ETRM is I believe by end of March for ADCOM. I'm not a long timer that bought below 1.00 earlier this year. But for those who did, it's definitely worth holding. Unfortunately for those who bought at near 2.00 on pump, it's gonna be a flip of coin that they might get break even as it reach near next catalyst.
I've traded ETRM several times since Feb in both directions. My latest trade is short near 2.00 over a week ago, because I believe it will consolidate near 1.50 area before start to climb towards next catalyst. Once I cover near my target, I will buy back for the run-up, but will not hold through the panel as I don't believe panel will give thumbs up. JMO.
" A lot of your argument really don't hold any water compared to a lot of people on this board that I have read and researched ."
Always consider MB for non other than entertainment. Seem to be more pumpers here than bashers.
If you bought before the pop, congrats. But many fell in the trap buying at the top due to the hype.
If you actually did your DD, you will notice some issues with the results. Along with current PPS, cash flow, debt, etc. The ADCOM isn't until March, long ways to go. Because of prior issues meeting the endpoints, and current result of 12% EWL and 5% TBL, pills would weight more.
I think there's higher chance that panel will not recommend. JMO
Disclosure: I've sold and just watching...
Biotech is NEWS driven.
Look at the chart for past 3 moths or so... And look at their market cap and financial...
GERN was PURE news driven, and was pumped heck out of it...